While, Cologuard, the first stool-based CRC screening test approved by the US Food and Drug Administration (FDA) includes two methylated DNA biomarkers, BMP3 and NDRG4. It could detect 92.3% of CRC and 42.4% of advanced adenomas with a specificity of 86.7% [13]. This evidence concerns the gene BMP3 and colorectal carcinoma.